Drug
Amelubant clinical trials
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 1998
How studies write it
Studies that test it under each name
Name
Studies by the year they started
13 studies that test it; most in 1999 (4)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 4 |
| 2000 | 4 |
| 2001 | 3 |
| 2002 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses amelubant is read from its arms, and is right about nine times in ten.
Testing it · 13
- Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02273440Written as BIIL 284 BS
- Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02273414Written as BIIL 284 BS - rising dose
- Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) PatientsCompletedPhase 1Boehringer IngelheimNCT02269189Written as BIIL 284 BS, high dose
- Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02268149Written as BIIL 284 BS
- Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02265627Written as BIIL 284 BS
- Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BSCompletedPhase 1Boehringer IngelheimNCT02265666Written as BIIL 284 BS Tablet FF
- Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02265640Written as BIIL 284 BS boli
- Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) PatientsCompletedPhase 1Boehringer IngelheimNCT02265679Written as BIIL 284 BS, low dose, pediatric patients
- Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02265653Written as BIIL 284 BS tablet C
- Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy MalesCompletedPhase 1Boehringer IngelheimNCT02265302Written as BIIL 284 oral solution
- Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid ArthritisCompletedPhase 2Boehringer IngelheimNCT02251210Written as BIIL 284 BS low dose
- The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial AsthmaCompletedPhase 2Boehringer IngelheimNCT02249312Written as BIIL 284 BS
- Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Boehringer IngelheimNCT02249338Written as BIIL 284 BS
Given in every arm · 1 — amelubant is usual care beside what is tested
Codes
What other systems call amelubant · ClinicalTrials.gg INT004334
- MeSH (NLM) C424425amelubantOne source NLM
- UNII (FDA) E0018IF0K4AMELUBANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27074432amelubantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73299AmelubantOne source FDA
- DrugBank DB06248One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C424425 | amelubant | One source NLM |
| UNII (FDA) | E0018IF0K4 | AMELUBANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074432 | amelubant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73299 | Amelubant | One source FDA |
| DrugBank | DB06248 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.